Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma

ObjectiveThe aim of this study is to compare gemcitabine (G) plus docetaxel (D) versus G plus anlotinib (A) for advanced soft tissue sarcoma (STS).MethodsWe retrospectively investigated 122 patients with locally advanced or metastatic STS who were treated with either G+D or G+A between July 2016 and...

Full description

Bibliographic Details
Main Authors: Zhiyong Liu, Xin Wang, Jiaqiang Wang, Peng Zhang, Chao Li, Bangmin Wang, Guancong Liu, Weitao Yao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
efficacy
safety
anlotinib
gemcitabine
docetatxel
soft tissue sarcoma (STS)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.922127/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.922127/full

Similar Items